Servier Appoints David K. Lee to Executive Committee
Discover our news
Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors
Servier Partners With Local Cancer Center to Support Research Graduate Students in the Boston Area
Servier to Present Data Across its Hematology Portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting
Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
Servier’s VORANIGO® (vorasidenib) tablets receives FDA approval as first targeted therapy for Grade 2 IDH-mutant glioma
Boston Business Journal Names Servier Pharmaceuticals a Best Places to Work for the Fourth Consecutive Year
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024